Tumores Gastrintestinais
Estudo randomizado | Efeitos da estratégia perioperatória de “enhanced recovery” após esofagectomia minimamente invasiva.
4 Jul, 2022 | 11:51hConteúdos relacionados:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Resumo visual: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease
Estudo randomizado | Em pessoas vivendo com HIV, o tratamento de lesões anais pré-cancerosas reduz mais da metade do risco de câncer anal.
22 Jun, 2022 | 21:45hComunicado de imprensa: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health
Estudo original: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Randomized trial showed that treating anal high-grade squamous intraepithelial lesions (HSILs) led to a 57% reduction in progression to anal cancer as compared with active surveillance. https://t.co/iulcskP61C pic.twitter.com/Q6Oqty3hgW
— NEJM (@NEJM) June 15, 2022
Análises clínicas e imunológicas de estudo de fase II | Sotigalimabe e/ou nivolumabe com quimioterapia no câncer pancreático metastático.
22 Jun, 2022 | 20:43hComunicado de imprensa: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Comentário no Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022
Avaliação radiômica do adenocarcinoma esofágico: revisão crítica de 18F-FDG PET/TC, PET/RM e da tomografia computadorizada.
21 Jun, 2022 | 12:33hEstudo com base de dados nacional de 5.055 pacientes | Desfechos oncológicos e de curto prazo da cirurgia de extração de espécime via orifício natural (natural orifice specimen extraction surgery – NOSES) para câncer colorretal na China.
19 Jun, 2022 | 15:23hComunicado de imprensa: Short-term and oncological outcomes of natural orifice specimen extraction surgery (NOSES) for colorectal cancer – Science China Press
Diretriz ASGE sobre o rastreamento de câncer pancreático em indivíduos com suscetibilidade genética.
19 Jun, 2022 | 14:14hComentário: New guidelines for pancreatic cancer screening – Beth Israel Deaconess Medical Center
Comentário no Twitter
Sawhney et al share "ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations." https://t.co/P6OtmhXr2D pic.twitter.com/vDHWfKCAiN
— GIE (@GIE_Journal) May 26, 2022
Causas do câncer hepático estão mudando ao redor do mundo: algumas ganham força, outras perdem.
19 Jun, 2022 | 13:17hComunicado de imprensa: Causes of Liver Cancer are Changing Around the World: Some Up, Some Down – UC San Diego Health
Estudo original: Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer – Cell Metabolism (link para o resumo – $ para o texto completo)
Estudo randomizado | Tremelimumabe com durvalumabe em carcinoma hepatocelular irressecável.
16 Jun, 2022 | 12:01hTremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma – NEJM Evidence
Comentário no Twitter
Durvalumab plus a single dose of tremelimumab increased overall survival by just over 2.5 months in patients with unresectable hepatocellular carcinoma who had not received previous systemic therapy. Read more about the HIMALAYA trial by @GABOUALFA et al.: https://t.co/8d2qp54OLt pic.twitter.com/AA1RlSEP2a
— NEJM Evidence (@NEJMEvidence) June 6, 2022
Estudo randomizado fase 2 | FOLFOXIRI (ácido folínico, 5-fluorouracila, oxaliplatina e irinotecano) antecipada com bevacizumabe com ou sem atezolizumabe no tratamento de pacientes com câncer colorretal metastático.
16 Jun, 2022 | 11:58hUpfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM
— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022
Revisão sistemática | Testes para sangue oculto nas fezes à base de guáiaco vs. testes imunoquímicos para rastreamento de câncer colorretal em indivíduos com risco médio.
14 Jun, 2022 | 13:48h
Comentário no Twitter
💩 Which faecal blood test is more accurate in detecting #bowelcancer and large polyps in population screening? https://t.co/U2mLfk7ARo This systematic review looks at the evidence from 63 studies including almost 4 million individuals. @CochranePH @CCGlobalAgeing @CochraneCRC pic.twitter.com/xQeeADgHql
— The Cochrane Library (@CochraneLibrary) June 7, 2022